Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804298 | 0.89 | CYP1A2 (0.45) | ITGA4ITGB7MME | |
| SCHEMBL6801616 | 0.88 | YAP1 (0.42) | PPARGPPARALTA4HLAP3PPARD | |
| SCHEMBL6915779 | 0.83 | NMBR (0.44) | LTA4HFFAR1 | |
| Lithium Ion SCHEMBL6804295 | 0.81 | MME (0.39) | ITGA4ITGB7MME | |
| SCHEMBL6203424 | 0.80 | PPARG (0.41) | PPARGPPARAITGA4ITGB7MME | |
| SCHEMBL6797773 | 0.73 | SOAT2 (0.48) | MME | |
| SCHEMBL8000823 | 0.72 | PPARG (0.63) | PPARGPPARALTA4HLAP3PPARD | |
| SCHEMBL28441594 | 0.71 | PPARA (0.62) | PPARGPPARALTA4HPPARDFFAR1 | |
| SCHEMBL28860722 | 0.70 | FFAR1 (0.64) | PPARGPPARALTA4HLAP3PPARD | |
| SCHEMBL28224291 | 0.70 | FFAR1 (0.64) | PPARGPPARALTA4HLAP3PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | PPARG 3817/4885PPARA 3913/4885LTA4H 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.